Literature DB >> 21937404

Effects of plasma from acute-on-chronic liver failure patients on immortalized human hepatocytes in vitro.

Lv Guoliang1, Zhang Anye, Zhao Lifu, Pan Xiaoping, Zhang Yimin, Yu Chengbo, Chen Yuemei, Li Lanjuan.   

Abstract

BACKGROUND/AIMS: The efficiency of bioartificial liver or cell transplantation for the treatment of liver failure may potentially be diminished by toxic agents accumulated in the patients blood. We investigated the effects of plasma from patients with acute-on-chronic liver failure on the structure and function of immortalized human hepatocytes (HepLL) in vitro.
METHODOLOGY: Plasma was pooled from 8 patients with acute or chronic liver failure. We utilized Transmission Electron Microscopy to observe the ultrastructure of HepLL cells and the activity of proliferation was examined by MTT assay. The percentage of apoptosis cells was measured through Annexin V-FITC apoptosis detection kit. The capacity for detoxification was analyzed using an ammonia elimination assay.
RESULTS: HepLL cells continue to proliferate, even when exposed to plasma derived from patients with 100% liver failure. No significant apoptosis was measured within 48h. The capacity for ammonia elimination was not statistically decreased until 36h incubation with liver failure plasma.
CONCLUSIONS: Although the toxic effects of plasma from acute-on-chronic liver failure patients should not be ignored, HepLL cells can maintain their function, when exposed to AoCLF plasma, for at least 24h and could be used as a suitable cell source for a bioartificial liver support system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937404     DOI: 10.5754/hge11034

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  Establishment and characterization of an immortalized human hepatocyte line for the development of bioartificial liver system.

Authors:  Qun Yan; Lijuan Deng; Xinmei Zhao; Liangying Ye; Yuxin Fang; Yan Meng; Zenan Wang; Xiaobei Luo; Side Liu; Aimin Li
Journal:  Cytotechnology       Date:  2018-02-12       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.